Daniel J. Drucker

Source: Wikipedia, the free encyclopedia.
For other people called Daniel Drucker, see Daniel Drucker (disambiguation).

Daniel Drucker
FRS, FRCPC, OC
Daniel Drucker at the Royal Society admissions day in London, July 2015
Born
Daniel Joshua Drucker

(1956-06-23) 23 June 1956 (age 67)[2]
Montreal, Quebec, Canada[2]
Alma materUniversity of Toronto (MD)[3]
Awards
Scientific career
Fields
Institutions
Website

Daniel Joshua Drucker (born 23 June 1956)

intestinal failure.[4]

Early life and education

Drucker was born and grew up in Montreal, went to high school in Ottawa, and then enrolled at the University of Ottawa, studying science.[5] In 1976, he moved to Toronto, where he studied medicine at the University of Toronto, graduating in 1980. He completed his internship at Johns Hopkins Hospital (1980–81), and completed his internal medicine and endocrinology residencies at the University of Toronto (1980–84).[5]

Career

Beginning in 1984, Drucker worked as a research fellow at the

cyclic AMP formation, insulin secretion, and insulin gene expression; notably, it did so only when glucose levels were elevated.[8][9]
In 1987 he returned to Toronto, taking on the position of assistant professor of medicine at the University of Toronto and working as a staff doctor.

Early in his career, Drucker discovered that hormones in the gut play important roles in the onset and development of

DPP4 inhibitors.[5]

In 1996, Drucker was one of several investigators who demonstrated that GLP-1 reduced food intake in preclinical studies. Notably, the experiments in the Drucker lab demonstrated that this action of GLP-1 in the brain required the functional canonical GLP-1 receptor.

small bowel of mice and rats.[13] He subsequently identified and characterized a DPP-4-resistant molecule, teduglutide,[14] that was ultimately developed and approved for the treatment of short bowel syndrome in adults and children, a disorder in which fluids are poorly absorbed after resection of the small intestine.[5][15]

Drucker joined the staff of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in 2006. In 2008 he conducted studies aimed at the development and testing of long-acting version of the diabetes medication exenatide.[16] He later studied the long-term effects of related weight-loss medicines on bowel health.[17] Drucker has also played key roles in the identification of the cardioprotective mechanisms of GLP-1 action,[18] and has identified multiple mechanisms linking GLP-1 to the reduction of inflammation[19][20].

He is a Canada Research Chair at the University of Toronto.

Awards and honours

Drucker has received many national and international awards in recognition of his research accomplishments revealing the mechanisms of action and therapeutic potential of enteroendocrine hormones. These include the Prix Galien Canada for outstanding academic research (2008), the Donald F. Steiner Award for Outstanding Diabetes Research from the University of Chicago (2007), the Clinical Investigator Award from the Endocrine Society (2009), the Claude Bernard Prize from the European Association for the Study of Diabetes (2012), the Oon International Award and Lecture from the University of Cambridge (2014), the Banting Medal for Scientific Achievement from the American Diabetes Association (2014) the Manpei Suzuki Foundation International Prize for Diabetes (2014), and the Harold Hamm International Prize for Biomedical Research in Diabetes (2019). In 2021 he was awarded the Canada Gairdner International Award.[21] In 2023, he received the Wolf Prize in Medicine[22] and the VinFuture Prize.[23]

Drucker was named an

Fellow of the Royal Society (FRS) in 2015.[5][1] and was elected to the National Academy of Medicine in 2023.[26]

Selected publications

References

  1. ^ a b c "Professor Daniel Drucker FRS". London: The Royal Society. Archived from the original on 2 May 2015.
  2. ^ a b c "DRUCKER, Prof. Daniel Joshua". Who's Who. Vol. 2016 (online Oxford University Press ed.). Oxford: A & C Black. (Subscription or UK public library membership required.)
  3. ^ "Daniel J. Drucker M.D, FRCPC, Clinical Advisor, Diartis Pharmaceuticals, Inc". Bloomberg L.P. 16 February 2024.
  4. ^ "This Toronto doctor is a superstar in the world of diabetes research — and he says it all started as a fluke". Toronto Star, By Joseph Hall, 7 February 2020
  5. ^ a b c d e f Anon (2015). "Professor Daniel Drucker FRS". London: royalsociety.org. Archived from the original on 17 November 2015.
  6. PMID 3525530
    .
  7. PMID 3543057
    .
  8. PMID 3033647
    .
  9. S2CID 233131461
    .
  10. PMID 10823914
    .
  11. PMID 15111503
    .
  12. S2CID 41872654
    .
  13. PMID 8755576
    .
  14. S2CID 35172107
    .
  15. ^ "Toronto endocrinologist named 2018 Principal Award winner by Manning Foundation". The Globe and Mail, Allan Maki, Calgary, 2 October 201
  16. ^ "Study: Once-a-week diabetes drug works better than twice-daily injection". Scientific American News Blog, By Susannah F. Locke on 8 September 2008
  17. ^ "Researchers investigate possible colon cancer risk for new generation of weight-loss drugs".Science News, 3 March 2015
  18. PMID 19151200
    .
  19. PMID 36027914
    .
  20. S2CID 266371336
    .
  21. ^ Canada Gairdner International Award 2021
  22. ^ Wolf Prize in Medicine 2023
  23. ^ Nhu, Quynh (21 December 2023). "Battery researchers win $3M Vietnamese awards". VnExpress.
  24. ^ "Order of Canada ceremony invests 48 new recipients, including NBA star Steve Nash". CBC News, 13 May 2016
  25. The Chronicle-Herald
    , 1 July 2015.
  26. ^ "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 9 October 2023. Retrieved 9 October 2023.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Daniel_J._Drucker&oldid=1215935584"